Monday, 24 February 2014
Summary Basis of Decision for Mekinist
Health Canada has issued a Notice of Compliance to GlaxoSmithKline Inc. for the drug product Mekinist. Based on Health Canada's review, the benefit/risk profile of Mekinist is favourable as a monotherapy for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Read more here.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment